| Page | |
| EDITORIALS |
| 978 | Missing out on effective care in idiopathic pulmonary fibrosis: Racial inequality in access to anti-fibrotic therapy
Amy Pascoe PhD, Natasha Smallwood BMedSci, MBBS, MSc, AFRACMA, FRCP(UK), FRACP, PhD, FThorSoc
10.1111/resp.14594
See related article |
| 980 | Sleep well with home automation
|
| COMMENTARIES |
| 983 | Clinical registries: Not yet perfect, but essential for a high-functioning health system
|
| 986 | Asthma registries: Tedious paperwork or a versatile tool for the generation of knowledge—Insights from the Australasian Severe Asthma Registry (ASAR)
|
| 989 | World Lung Day 2023—Access to prevention and treatment for all, leave no one behind
David C L Lam MD, PhD, FAPSR, Chul-Gyu Yoo MD, PhD, Yoichi Nakanishi MD, PhD, Kwun M Fong MBBS, PhD
10.1111/resp.14598 |
| INVITED REVIEW SERIES |
| The Future of Asthma |
| 992 | Asthma in developing countries in the Asia-Pacific Region (APR)
|
| Treatable Traits - Personalized Medicine for Life in Airway Disease |
| 1005 | Treatable traits for long COVID
|
| POSITION PAPER |
| 1023 | Asthma and landscape fire smoke: A Thoracic Society of Australia and New Zealand position statement
Vanessa M McDonald, Gregory Archbold, Tesfalidet Beyene, Bronwyn K Brew, Peter Franklin, Peter G Gibson, John Harrington, Philip M Hansbro, Fay H Johnston, Paul D Robinson, Michael Sutherland, Deborah Yates, Graeme R Zosky, Michael J Abramson
10.1111/resp.14593 |
| ORIGINAL ARTICLES |
| Interstitial Lung Disease |
| 1036 | Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis
Joy Zhao, Joseph Fares, Gautam George, Arlene Maheu, Giorgos Loizidis, Jesse Roman, Daniel Kramer, Michael Li, Ross Summer
10.1111/resp.14563
We uncovered racial and ethnic disparities in the treatment of IPF. Black patients had lower antifibrotic use compared to White, Hispanic and Asian patients, even among older patients and those with lower lung function. White IPF patients on antifibrotics had a lower mortality, while treated and untreated Hispanic, Asian and Black IPF patients had similar mortality risk.
See related See related editorial |
| 1043 | Analysis of tissue lipidomics and computed tomography pulmonary fat attenuation volume (CTPFAV) in idiopathic pulmonary fibrosis
Marissa O'Callaghan, John Duignan, Elizabeth J Tarling, Darragh K Waters, Megan McStay, Orla O'Carroll, James P Bridges, Elizabeth F Redente, Alessandro N Franciosi, Emmet E McGrath, Marcus W Butler, Jonathan D Dodd, Aurelie Fabre, David J Murphy, Michael P Keane, Cormac McCarthy
10.1111/resp.14582
Aberrant cell lipid metabolism has been described in IPF but the underlying mechanisms are underexplored. In this study, chest CT is used to assess pulmonary fat attenuation volume (PFAV) in IPF. CTPFAV correlates with spirometry and IPF radiological markers. With further validation, CTPFAV could be used as a disease severity biomarker. |
| Interventional Pulmonology |
| 1053 |
Safety and efficacy of bronchial thermoplasty in Australia 5 years post-procedure
Monica Hatch, Paul Lilburn, Caroline Scott, Alvin Ing, David Langton
10.1111/resp.14568
In an Australian cohort of very severe asthmatics treated with bronchial thermoplasty, maintenance of effect was seen at 5 years with sustained reductions in ACQ score and exacerbation frequency. When compared with baseline CT imaging, some cases demonstrated bronchial dilatation, without clinical features of bronchiectasis. |
| Lung Cancer |
| 1060 | Factors associated with failure of cardiopulmonary function recovery after lung cancer surgery
Sunga Kong, Sumin Shin, Yeong Jeong Jeon, Genehee Lee, Jong Ho Cho, Hong Kwan Kim, Young Mog Shim, Juhee Cho, Danbee Kang, Hye Yun Park
10.1111/resp.14581
Reduced moderate-to-vigorous physical activity (MVPA), and persistent low MVPA from baseline to the two-week after surgery as well as baseline PA were substantial predictors for the failure of cardiopulmonary function (CPF) recovery following lung cancer surgery. This highlights the vital role of perioperative physical activity for CPF recovery. |
| 1069 | Auto-adjusted versus fixed positive airway pressure in patients with severe OSA: A large randomized controlled trial
Vanessa Bironneau, Pierre Ingrand, Sandrine Pontier, Carmen Iamandi, Laurent Portel, Francis Martin, Anne Mallart, Lionel Lerousseau, Didier Alfandary, Virginie Levrat, Florence Portier, Renaud Tamisier, Frédéric Goutorbe, Claudio Rabec, François Codron, Guy Auregan, Magalie Mercy, Valérie Attali, Frank Soyez, Claire Launois, Didier Recart, Marie-Françoise Vecchierini, Frédéric Gagnadoux, Jean-Claude Meurice, on behalf of the PREDIVARIUS group
10.1111/resp.14569
This prospective randomized controlled clinical study evaluated the 3 month-efficacy of continuous positive airway pressure (CPAP) used either in fixed CPAP or auto-adjusted (APAP) mode by including 801 patients with severe OSA. The two CPAP modes were equally effective and tolerated in severe OSA patients.
See related editorial |
| FORUM AND DEBATE |
| Personal Reflections |
| 1078 | Can we predict asthma exacerbations?
|
| 1080 | Football and respiratory medicine—Time to start kicking goals
Natasha Smallwood BMedSci, MBBS, MSc, AFRACMA, FRCP, FRACP, PhD, FThorSoc
10.1111/resp.14600 |
| Letters from Asia-Pacific and Beyond |
| 1082 | Letter from Taiwan
|
| 1084 | Letter from Mexico: A 2023 post-COVID update
|
